WESTON, Florida, September 12, 2018 /PRNewswire/ —
Pyramidion Technology Group, Inc. (OTC: PYTG) today announces that Dr. David M. Feldbaum MD, Fellow, American College of Surgeons (FACS), has been appointed to the Board of Advisors for PYTG.
David M. Feldbaum MD, FACS is certified in vascular surgery by the American Board of Surgery. Dr. Feldbaum completed a surgical residency at Montefiore Medical Center/Albert Einstein College of Medicine in New York City, and a vascular surgery fellowship at the Carolinas Heart Institute in North Carolina. He is affiliated with the Memorial Healthcare System, and Westside Regional Medical Center. He is also a member of the voluntary faculty clinical instructor of surgery at the University of Miami School of Medicine.
Dr. Feldbaum’s presence on the Board of Advisors seeks to bolster its already credential-filled advisory capacity by offering instrumental input on the implementation of whole-care wellness plans, and specific case-relevant treatment plans, related to his area of expertise. Dr. Feldbaum has a unique interest in Medical Cannabis affairs and is a strong advocate of the use of Cannabidiol (CBD) products as part of a health and wellness program for many patients.
CBD research has provided evidentiary findings demonstrating its potentially beneficial symptomatic relief for vast range of ailments, including rheumatoid arthritis, diabetes, alcoholism, post-traumatic stress disorder, epilepsy, antibiotic-resistant infections, neurological disorders, and muscular dystrophy, to name a few.
“I am pleased to take on this new position with PYTG and the CBD containing product lines of LeafyWell. I feel that we can make a difference in how these products are designed, created, and implemented in order to maximize the positive health-related benefits for many of us,” states Dr. Feldbaum.
PYTG’s advisory board has been charged with providing guidance and insight on formula creation along with implementation plans for the company’s products containing CBD oil including delivery methods such as tinctures, creams, edible products, drinks, and others. Aligning with medical-goal related product development, Dr. Feldbaum’s expertise of the cardiovascular system and cardiovascular health should prove to be an instrumental and integral part of the company’s future advances in product lines creation and development.
“Dr. Feldbaum is a leader in his field and as one of the most-well respected cardiovascular surgeons, we are certain his knowledge of the human cardiovascular system and responses to CBD oil containing products will lead to our continued creation of the most well-informed product lines around,” states Carlos Hurtado CEO of PYTG.
On the appointments, CEO Carlos Hurtado said, “Pyramidion has a mission to make cannabis available to any patient who can benefit from safe and reliable sources. The addition of these Reputed Physicians to our Medical Board will lead to even greater access for patients to the best CBD Products in the Market and built a solid Doctors-Patient Relationship and changing their life for better health.
About Pyramidion Technology Group, Inc
Pyramidion Technology Group, Inc. (“PYTG” or the “Company”) is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our
overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
For more information on PYTG, please visit the Company’s website at https://www.pytgcorp.com.com/.
To be added to the Company investor email list, please email email@example.com with PYTG in the subject line.
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance
on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
Investor Contact: firstname.lastname@example.org